OOIR: Observatory of International Research

Papers

(The H4-Index of JNCI-Journal of the National Cancer Institute is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Correction to: TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer	329
Correction to: RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study	221
Correction to: ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications	189
Corrigendum to: Receptivity to a Nurse-Led Symptom Management Intervention among Highly Symptomatic Patients with Cance	178
Corrigendum to: Realizing the Promise of Personalized Colorectal Cancer Screening in Practice	132
BRCA1/2 germline sequencing in children and adolescents with cancer: it is the context that matters	126
The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045	123
Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study	121
Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline	120
Risk factors for second primary breast cancer by laterality, age, and race and ethnicity	117
Response to Liu and Zhang	109
Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data	105
Disparities in the availability of and access to neuro-oncology trial-supporting infrastructure in the United States	105
Lower survival for surgical treatment of human papillomavirus–related oropharynx cancer at community cancer centers	86
Stat Bite: Convergence of long-term trends in cervix uteri cancer incidence among Black and White women from 1975 to 2021	66
Association of immunoglobulin E levels with glioma risk and survival	62
Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort	61
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer	60
Retraction and Replacement of: Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening	59
Effect of chronic disease on racial difference in COVID-19–associated hospitalization among cancer patients	59
Surgical Care for Older Adults: The Importance of Patient-Centered Outcomes in Daily Practice	59
Publisher’s Note	58
Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a US cohort	57
Advancing rapid cycle research in cancer care delivery: a National Cancer Institute workshop report	52
Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance)	51

The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer	49
Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds	49
Correction to: RE: Grade Migration of Prostate Cancer in the United States During the Last Decade	45
Reviewers	45
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations	45
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial	44
Response to Liu, Xiao, Liu, et al.	43
Colon, colorectal and all cancer incidence increase in the Young due to appendix reclassification	42
Response to Lehrer	42
RE: Use of artificial intelligence for cancer clinical trial enrollment	41
Editor’s Note to: Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex	41
Stat Bite: Estimated cumulative risk of female breast cancer incidence and mortality (ages 0-74) in 2022	40
Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia	40
Housing Insecurity Among Patients With Cancer	40
Obligate and Potential Precursors of Melanoma	40
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130	40